Foghorn Therapeutics Investor Relations Material

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapies targeting the chromatin regulatory system, which plays a critical role in gene expression and cellular identity. The company leverages its proprietary Gene Traffic Control platform to gain an integrated understanding of how chromatin regulation affects disease, enabling it to identify and develop potential drug candidates. Foghorn's research focuses on treating genetically determined dependencies in various cancers, including hematologic malignancies and solid tumors. The company has collaborations with major pharmaceutical firms to further its therapeutic pipeline. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.